Video

Dr. Gradishar Discusses the Treatment of HER2+ Breast Cancer

William J. Gradishar, MD, interim chief of hematology and oncology, Department of Medicine, Betsy Bramsen Professorship of Breast Oncology, professor of medicine (hematology and oncology), Northwestern University's Feinberg School of Medicine, discusses the treatment of HER2-positive breast cancer.

William J. Gradishar, MD, interim chief of hematology and oncology, Department of Medicine, Betsy Bramsen Professorship of Breast Oncology, professor of medicine (hematology and oncology), Northwestern University's Feinberg School of Medicine, discusses the treatment of patients with HER2-positive breast cancer.

There are some patients who are not candidates for chemotherapy, or cannot tolerate it due to other medical comorbities, says Gradishar. Other options for these patients would be giving both hormonal therapy and HER2-targeted therapy simultaneously, such as lapatinib (Tykerb) and letrozole or anastrozole and trastuzumab (Herceptin).

More recently, dual targeting of HER2 along with an hormonal therapy has shown promise as a treatment for these patients. The phase III results from the ALTERNATIVE trial showed the median progression-free survival was 11 months (95% CI, 8.3-13.8) for postmenopausal women with hormone receptor-positive, HER2-positive metastatic breast cancer assigned to lapatinib plus trastuzumab plus an aromatase inhibitor (AI) compared with 5.7 months (95% CI, 5.5-8.4) for patients assigned to trastuzumab plus an AI.

There has also been work looking at combining hormonal therapy with CDK 4/6 inhibitors and HER2-targeted therapy, Gradishar adds.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Latest CME

View All
Addressing Unmet Needs in HER2+ Metastatic BTC
Video

Addressing Unmet Needs in HER2+ Metastatic BTC

Apr 24th 2025 - Apr 25th 2026

online-activity
Optimizing Today and Looking to Tomorrow in Metastatic CRPC—Homing in on EZH2
Video

Optimizing Today and Looking to Tomorrow in Metastatic CRPC—Homing in on EZH2

Apr 23rd 2025 - Apr 24th 2026

online-activity
(CME Track) Clinical Consultations™: Framing a New Approach to Geographic Atrophy Management – Expert Insights into Recent Developments
Video

(CME Track) Clinical Consultations™: Framing a New Approach to Geographic Atrophy Management – Expert Insights into Recent Developments

Apr 23rd 2025 - Apr 24th 2026

online-activity